Correlation of CTGF gene promoter methylation with CTGF expression in type 2 diabetes mellitus with or without nephropathy

Zhang,Hao; Cai,Xu; Yi,Bin; Huang,Jing; Wang,Jianwen; Sun,Jian

doi:10.3892/mmr.2014.2067

Correlation of CTGF gene promoter methylation with CTGF expression in type 2 diabetes mellitus with or without nephropathy

Authors:
- Hao Zhang
- Xu Cai
- Bin Yi
- Jing Huang
- Jianwen Wang
- Jian Sun
View Affiliations

Affiliations: Department of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China, Department of Nephrology, The Second People's Hospital of Guangdong Province, Guangzhou, Guangdong 510317, P.R. China
Published online on: March 24, 2014 https://doi.org/10.3892/mmr.2014.2067
Pages: 2138-2144
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence shows that DNA methylation is involved in the development and progression of diabetes mellitus (DM) and its complications. Previous studies conducted by our group have indicated that high glucose levels may induce the demethylation process of the connective tissue growth factor (CTGF) gene promoter and increase the expression of CTGF in human glomerular mesangial cells. Based on these findings, the aim of the present study was to investigate the methylation level of genomic DNA and the CTGF promoter in patients with type 2 DM and to analyze its possible correlation with CTGF expression. Methylation levels of the whole genomic DNA were detected by high‑performance liquid chromatography in a non‑diabetes control (NDM) group (n=29), a diabetes without nephropathy (NDN) group (n=37) and a diabetes with nephropathy (DN) group (n=38). CTGF promoter methylation levels were detected by methylation‑specific polymerase chain reaction and bisulfite sequencing. The levels of serum CTGF were assessed using the enzyme‑linked immunosorbent assay. The methylation levels of the whole genomic DNA were not significantly different among the three groups. However, the CTGF methylation levels in the two diabetes groups were significantly lower than those in the NDM group (P<0.05), with the lowest methylation level in the DN group (P<0.05). The CTGF protein levels in the DN group were significantly higher than those in the NDM and NDN groups (P<0.05). Levels of CTGF were negatively correlated with the estimated glomerular filtration rate (eGFR) and the methylation level of the promoter, while they were positively correlated with age, urinary albumin‑to‑creatinine ratio (UACR), blood urea nitrogen, creatinine, fasting blood sugar and postprandial blood glucose. Multiple stepwise regression analysis showed that CTGF expression was associated with the UACR, CTGF methylation level and eGFR. DNA methylation is a regulatory mechanism of CTGF expression, which is decreased in patients with DM, particularly in those with DN, and may contribute to the pathogenesis of nephropathy.

View Figures

View References

1	Melendez-Ramirez LY, Richards RJ and Cefalu WT: Complications of type 1 diabetes. Endocrinol Metab Clin North Am. 39:625–640. 2010. View Article : Google Scholar
2	Gheissari A, Javanmard SH, Shirzadi R, Amini M and Khalili N: The effects of blocking Angiotensin receptors on early stages of diabetic nephropathy. Int J Prev Med. 3:477–482. 2012.PubMed/NCBI
3	Hirst JA, Taylor KS, Stevens RJ, et al: The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int. 81:674–683. 2012. View Article : Google Scholar : PubMed/NCBI
4	Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C and Attia J: Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 55:566–578. 2012. View Article : Google Scholar : PubMed/NCBI
5	Tonna S, El-Osta A, Cooper ME and Tikellis C: Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. Nat Rev Nephrol. 6:332–341. 2010. View Article : Google Scholar : PubMed/NCBI
6	Reddy MA and Natarajan R: Epigenetics in diabetic kidney disease. J Am Soc Nephrol. 22:2182–2185. 2011. View Article : Google Scholar : PubMed/NCBI
7	Maier S and Olek A: Diabetes: a candidate disease for efficient DNA methylation profiling. J Nutr. 132(Suppl 8): 2440S–2443S. 2002.PubMed/NCBI
8	Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S and Savage DA: Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genomics. 3:332010. View Article : Google Scholar : PubMed/NCBI
9	Guha M, Xu ZG, Tung D, Lanting L and Natarajan R: Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 21:3355–3368. 2007. View Article : Google Scholar : PubMed/NCBI
10	Nguyen TQ, Tarnow L, Jorsal A, et al: Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care. 31:1177–1182. 2008. View Article : Google Scholar : PubMed/NCBI
11	Kikuchi R, Tsuda H, Kanai Y, et al: Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res. 67:7095–7105. 2007. View Article : Google Scholar
12	Chiba T, Yokosuka O, Fukai K, et al: Identification and investigation of methylated genes in hepatoma. Eur J Cancer. 41:1185–1194. 2005. View Article : Google Scholar : PubMed/NCBI
13	Yi B, Zhang H, Zhou H, Cai X, Sun J and Liu Y: High glucose induce the demethylation of CTGF promoter and gene expression. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 27:747–750. 2011.(In Chinese).
14	Bennett PH: Impact of the new WHO classification and diagnostic criteria. Diabetes Obes Metab. (Suppl 2): S1–S6. 1999. View Article : Google Scholar : PubMed/NCBI
15	National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 60:850–886. 2012. View Article : Google Scholar : PubMed/NCBI
16	Nichols GA, Vupputuri S and Lau H: Medical care costs associated with progression of diabetic nephropathy. Diabetes Care. 34:2374–2378. 2011. View Article : Google Scholar : PubMed/NCBI
17	Bechtel W, McGoohan S, Zeisberg EM, et al: Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 16:544–550. 2010. View Article : Google Scholar : PubMed/NCBI
18	Dwivedi RS, Herman JG, McCaffrey TA and Raj DS: Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int. 79:23–32. 2011. View Article : Google Scholar : PubMed/NCBI
19	Laborie LB, Mackay DJ, Temple IK, Molven A, Søvik O and Njølstad PR: DNA hypomethylation, transient neonatal diabetes, and prune belly sequence in one of two identical twins. Eur J Pediatr. 169:207–213. 2010. View Article : Google Scholar : PubMed/NCBI
20	Varrault A, Bilanges B, Mackay DJ, et al: Characterization of the methylation-sensitive promoter of the imprinted ZAC gene supports its role in transient neonatal diabetes mellitus. J Biol Chem. 276:18653–18656. 2001. View Article : Google Scholar : PubMed/NCBI
21	Nanayakkara PW, Kiefte-de Jong JC, Stehouwer CD, et al: Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2–4 chronic kidney disease. Nephrol Dial Transplant. 23:2586–2592. 2008.PubMed/NCBI
22	Kuroda A, Rauch TA, Todorov I, et al: Insulin gene expression is regulated by DNA methylation. PLoS One. 4:e69532009. View Article : Google Scholar : PubMed/NCBI
23	Yang BT, Dayeh TA, Kirkpatrick CL, et al: Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets. Diabetologia. 54:360–367. 2011. View Article : Google Scholar : PubMed/NCBI
24	Du J, Wang L, Liu X, et al: Janus kinase 2/signal transducers and activators of transcription signal inhibition regulates protective effects of probucol on mesangial cells treated with high glucose. Biol Pharm Bull. 33:768–772. 2010. View Article : Google Scholar : PubMed/NCBI
25	Li X, Liu W, Wang Q, et al: Emodin suppresses cell proliferation and fibronectin expression via p38MAPK pathway in rat mesangial cells cultured under high glucose. Mol Cell Endocrinol. 307:157–162. 2009. View Article : Google Scholar : PubMed/NCBI
26	El Mesallamy HO, Ahmed HH, Bassyouni AA and Ahmed AS: Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy. Clin Biochem. 45:646–650. 2012.PubMed/NCBI
27	Tam FW, Riser BL, Meeran K, Rambow J, Pusey CD and Frankel AH: Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine. 47:37–42. 2009. View Article : Google Scholar : PubMed/NCBI